Friday 6 November 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
39.62
0.14
−0.35%
Follow MDLN
Alert me
Medline Inc. (MDLN) Net income
Medline Inc.'s net income for fiscal 2025 was $1.2B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.9B. Medline Inc. ranks 2nd of 51 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.2B | (3.58%) |
| FY2024 | $1.2B | 412.82% |
| FY2023 | $234.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $318.0M | 128.78% |
| Jun 2026 | $139.0M | (41.84%) |
| Mar 2026 | $239.0M | (79.34%) |
| Dec 2025 | $1.2B | 247.45% |
| 2 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| ISRG Intuitive Surgical, Inc. compare | $3.0B |
| MDLN Medline Inc. | $1.9B |
| RMD ResMed Inc. compare | $1.6B |
| BDX Becton, Dickinson and Company compare | $942.0M |
| ALC Alcon compare | $643.0M |
| WST West Pharmaceutical Services, Inc. compare | $638.9M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| SOLV Solventum Corporation compare | $156.0M |
| BAX Baxter International Inc. compare | −$723.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on MDLN
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement